Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?. Can IBD Today 2023, 1 (S05), 2–7. https://doi.org/10.58931/cibdt.2023.1S0510.